ClinicalTrials.gg
Not yet recruitingNCT07789522HRMM-001Updated Aug 27, 2026

Safety and Efficacy of Elranatamab Plus Isatuximab, Bortezomib, and Lenalidomide in Ultra-High-Risk Multiple Myeloma

A Phase 2 interventional study of anti-BCMA/CD3 bispecific antibody in Multiple Myeloma (MM), sponsored by Institute of Hematology & Blood Diseases Hospital, China. Not yet recruiting. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2026-08-27.

Sponsored by Institute of Hematology & Blood Diseases Hospital, China · Phase 2, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
15
Allocation
Not applicable
Ages
18 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 40 studies in Multiple Myeloma by Institute of Hematology & Blood Diseases Hospital, China — 32 open to participants now, 35 under way, none of them phase 3. Multiple Myeloma · Institute of Hematology & Blood Diseases Hospital, China.

Planned enrollment
28th of 36
15 · median 24
Started
2026
with 15 others
Phase 2
18 of 40
15 open now
Primary completion
2027-10
later than 21 of 34 live
Registered
36th of 40
by date

Among the 40 studies in Multiple Myeloma by Institute of Hematology & Blood Diseases Hospital, China, this one is the 28th largest by planned enrollment of the 36 interventional ones that give a count, is one of 16 that started in 2026, is one of 18 in phase 2, reaches primary completion later than 21 of the 34 other live ones, and was the 36th registered.

Multiple Myeloma

3,764 studies on the registry are indexed under Multiple Myeloma; 768 are open to participants now.

Browse Multiple Myeloma studies →

Open to participants now

32 of the 40 studies in Multiple Myeloma by Institute of Hematology & Blood Diseases Hospital, China are open now, in 1 country. Recruiting first, the newest first:

27 more — sign in →

By country, each count listing its studies:

All 32 open studies →

Where they have run

Who these studies take

Of the 583 Multiple Myeloma studies recruiting now, 428 (73%) set no upper age limit and 106 (18%) stop at 75 or younger; 36 take children under 18; 24 take healthy volunteers.

This study: 18 Years to 70 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 40 studies in Multiple Myeloma by Institute of Hematology & Blood Diseases Hospital, China, or all of them as a file.
02

Study summary

This is a prospective, single-arm, single-center interventional study designed to evaluate the safety and efficacy of Elra-Isa-VR in patients with newly diagnosed ultra-high-risk multiple myeloma.

03

Conditions studied

  • Multiple Myeloma (MM)

Browse trials for

Keywords

  • BCMA/CD3 bispecific antibody
  • Elranatamab
04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. The subject voluntarily signs the form (ICF).
  2. Aged 18-70 years.
  3. (ECOG) performance status of 0-2.

Newly diagnosed multiple myeloma according to the International Myeloma Working Group (IMWG) diagnostic criteria, with meeting at least one of the following criteria:

  1. Serum M-protein ≥1.0 g/dL
  2. Urine M-protein ≥200 mg/24 hours
  3. Serum involved free light chain ≥10 mg/dL with an abnormal serum free light-chain ratio 4.High-risk multiple myeloma according to the Consensus Genomic Staging (CGS) system published by the International Myeloma Society-International Myeloma Working Group (IMS-IMWG), or peripheral blood plasma cells ≥2%, or an extramedullary soft-tissue mass (EME). High-risk CGS is defined by at least one of the following criteria:

(1)del(17p) with a clonal fraction >20% and/or a TP53 mutation (2)An IGH translocation [t(4;14), t(14;16), or t(14;20)] combined with 1q+ or del(1p32) (3)del(1p32), defined as monoallelic deletion combined with 1q+ or biallelic deletion (5)β2-microglobulin ≥5.5 mg/L with a normal serum creatinine level

Exclusion criteria

Exclusion Criteria:

  1. Concurrent plasma cell leukemia, central nervous system involvement, or amyloidosis.
  2. Peripheral neuropathy of Grade >1, or Grade 1 peripheral neuropathy with pain. Prior or ongoing systemic therapy or stem cell transplantation for symptomatic multiple myeloma, except for the emergency use of a short course of equivalent to dexamethasone 40 mg/day for 4 days, provided that the course is completed within 14 days before randomization.
  3. Any to, or a history of life-threatening allergy, , or intolerance to, any study drug or its .
  4. Pregnant or breastfeeding, or planning to become pregnant during participation in the study or within 6 months after the last dose of any study treatment.
  5. Planning to father a child during participation in the study or within 100 days after the last dose of any component of the study treatment regimen.
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
15 participants (estimated)

Study arms

  • Experimental
    BsAbs-treatment group

    Drug: anti-BCMA/CD3 bispecific antibody

Interventions

06

What researchers measure

Primary outcomes

  1. Minimal residual disease (MRD) negativity rate

    Time frame: 9 months

Secondary outcomes

  1. Adverse events and serious adverse events

    Time frame: Up to 2 year

  2. Sustained MRD negativity rate

    Time frame: Up to 2 year

  3. Overall response rate (ORR)

    Time frame: Up to 2 year

  4. Complete response rate (CR)

    Time frame: Up to 2 year

  5. Progression-free survival (PFS)

    Time frame: Up to 2 year

  6. Duration of response (DoR)

    Time frame: Up to 2 year

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Oct 2026; primary completion for Oct 2027, 12 months later.

Of 411 non-industry phase 2 interventional studies under Multiple Myeloma, half reached primary completion within 59 months of starting (the median), counting those still running; a quarter within 40 and three quarters within 96. This study's planned 12 months is below that.

Counting every sponsor, half of 504 studies reached it within 57 months; a quarter within 35 and three quarters within 95.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 24, 2026
First posted
Aug 27, 2026
StartEst.
Oct 1, 2026
Primary completionEst.
Oct 9, 2027
CompletionEst.
Oct 30, 2028
Last update
Aug 27, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 27, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07789522
Responsible party
Sponsor
First posted
Aug 27, 2026
Start date
Oct 1, 2026 (estimated)
Primary completion
Oct 9, 2027 (estimated)
Completion
Oct 30, 2028 (estimated)
Last update
Aug 27, 2026

Study contacts

Gang An
Contact
angang@ihcams.ac.cn
86-022-23909171

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Anti-BCMA/CD3 Bispecific Monoclonal Antibody

Start the discussion